Cargando…
ODP571 Blockade of ErbB-2 Nuclear Function Induces the Interferon Signaling Pathway in Breast Cancer Models Resistant to Trastuzumab
ErbB-2, a member of ErbB family of receptor tyrosine kinases, is a key oncogenic driver in breast cancer. Despite clinical efficiency of ErbB-2-targeted therapies (trastuzumab, TZ), resistance to drugs is a major issue in the clinic. While ErbB-2 is mainly a plasma membrane-bound receptor, it also m...
Autores principales: | Elizalde, Patricia V, Cordo Russo, Rosalia, Madera, Santiago, Merin, Sharon S, Chervo, María F, Ebrahimie, Esmaeil, Selth, Luke, Chiauzzi, Violeta A, Dupont, Agustina, Barchuk, Sabrina, Figurelli, Silvina, Lopez Della Vecchia, Daniel, Guzmán, Pablo, Roa, Juan C, Levit, Claudio, Lebersztein, Gabriel, Anfuso, Fabiana, Proietti, Cecilia J, Schillaci, Roxana, Hickey, Theresa E, Tilley, Wayne D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628591/ http://dx.doi.org/10.1210/jendso/bvac150.1817 |
Ejemplares similares
-
Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer
por: Madera, Santiago, et al.
Publicado: (2022) -
ODP551 Halting ErbB-2 Isoforms Retrograde Transport to the Nucleus as a New Theragnostic Approach for Triple Negative Breast Cancer
por: Elizalde, Patricia Virginia, et al.
Publicado: (2022) -
Halting Retrograde Transport Excludes ErbB-2 From the Nucleus Abrogating Tumor Growth in Triple Negative Breast Cancer
por: Madera, Santiago, et al.
Publicado: (2021) -
ODP441 NErbB-2 and Androgen Receptor Regulate a Gene Signature Involved in Immune Response and Favorable Outcome in TNBC
por: Elizalde, Patricia, et al.
Publicado: (2022) -
SUN-122 Nuclear PDCD4 Expression Predicts Good Clinical Outcome in Luminal A-Like and Luminal B-Like Breast Cancer Subtypes
por: Madera, Santiago, et al.
Publicado: (2020)